Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Invested Capital (2016 - 2025)

Arcadia Biosciences' Invested Capital history spans 12 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 33.47% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, down 33.47%, while the annual FY2025 figure was $4.1 million, 33.47% down from the prior year.
  • Invested Capital reached $4.1 million in Q4 2025 per RKDA's latest filing, down from $5.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $46.8 million in Q1 2021 to a low of $4.1 million in Q4 2025.
  • Average Invested Capital over 5 years is $19.5 million, with a median of $16.1 million recorded in 2023.
  • Peak YoY movement for Invested Capital: skyrocketed 282.74% in 2021, then crashed 60.81% in 2025.
  • A 5-year view of Invested Capital shows it stood at $31.3 million in 2021, then tumbled by 32.99% to $20.9 million in 2022, then crashed by 39.36% to $12.7 million in 2023, then crashed by 51.01% to $6.2 million in 2024, then plummeted by 33.47% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Invested Capital are $4.1 million (Q4 2025), $5.4 million (Q3 2025), and $4.5 million (Q2 2025).